"JPMorgan Chase Secures $1.2 Billion Financing for Alkermes' $2.1 Billion Acquisition of Avadel Pharmaceuticals"

"Simpson Thacher is advising JPMorgan Chase Bank on a $1.2 billion bridge financing for Alkermes plc's planned acquisition of Avadel Pharmaceuticals plc, valued at approximately $2.1 billion. The deal is expected to close in the first quarter of 2026, pending certain conditions. Alkermes focuses on developing innovative neuroscience medicines, while Avadel specializes in transforming medications to improve patient outcomes, notably with its FDA-approved product LUMRYZ™ for narcolepsy."

Simpson Thacher & Bartlett LLP represented JPMorgan Chase Bank, N.A. in connection with committed debt financing for Alkermes plc’s proposed acquisition of Avadel Pharmaceuticals plc. The transaction, which values Avadel at approximately $2.1 billion, involves a committed financing package that includes a $1.2 billion bridge facility. The deal is anticipated to close in the first quarter of 2026, pending the fulfillment of certain closing conditions. The Simpson Thacher team involved in this transaction includes the following lawyers: - Banking and Credit: Jennifer Albrecht, Alexandra Kaplan, Sophie Skinner, Roman Ibragimov, Aaron Gurley, and Susan Murley. - Capital Markets: John Ericson, Erica Yoon, Jeryne Fish, and Louise Choi. - Healthcare/FDA: Vanessa Burrows, Alison Peters, and Jacob Madden. - M&A: Malik Ladhani, Haley O’Connor, and Avery Golombek. - Intellectual Property: Courtney Welshimer, Corina Holland, Matthew Richardson, and Margerite Blase. - Tax: Michael Mann.

"JPMorgan Chase Secures $1.2 Billion Financing for Alkermes' $2.1 Billion Acquisition of Avadel Pharmaceuticals"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads